BR0316310A - Composições farmacêuticas tendo um veìculo modificado - Google Patents

Composições farmacêuticas tendo um veìculo modificado

Info

Publication number
BR0316310A
BR0316310A BR0316310-5A BR0316310A BR0316310A BR 0316310 A BR0316310 A BR 0316310A BR 0316310 A BR0316310 A BR 0316310A BR 0316310 A BR0316310 A BR 0316310A
Authority
BR
Brazil
Prior art keywords
composition
liquid carrier
pharmaceutical compositions
modified
vehicle
Prior art date
Application number
BR0316310-5A
Other languages
English (en)
Inventor
Ondrej Hendl
Susan Marie Machkovech
Niki Ann Waldron
Nancy Jean Britten
Dannette Marie Shaw
Alanta Lea Lary
Thomas Joseph Yellig
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0316310(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BR0316310A publication Critical patent/BR0316310A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS TENDO UM VEìCULO MODIFICADO". Uma composição compreendendo: (a) um a três agentes bioativos; e (b) um veículo compreendendo: (i) um carreador líquido modificado, e (ii) um carreador líquido não modificado em que a proporção em volume do carreador líquido modificado para o carreador líquido não modificado está entre 0,00001:99,99999 até menos de 0,01:99,99, que produz a composição com propriedades de liberação controlada predizíveis, e em que imediatamente após a fabricação da composição, a referida composição pode ser administrada a um hospedeiro tal que o um a três agentes bioativos são libertados para o hospedeiro em uma base controlada.
BR0316310-5A 2002-11-19 2003-11-17 Composições farmacêuticas tendo um veìculo modificado BR0316310A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42768002P 2002-11-19 2002-11-19
PCT/IB2003/005234 WO2004045646A1 (en) 2002-11-19 2003-11-17 Pharmaceutical compositions having a modified vehicle

Publications (1)

Publication Number Publication Date
BR0316310A true BR0316310A (pt) 2005-09-27

Family

ID=32326579

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316310-5A BR0316310A (pt) 2002-11-19 2003-11-17 Composições farmacêuticas tendo um veìculo modificado

Country Status (18)

Country Link
US (1) US7659061B2 (pt)
EP (1) EP1569693B1 (pt)
JP (1) JP4656945B2 (pt)
KR (1) KR20050085037A (pt)
CN (2) CN103272243A (pt)
AR (1) AR042193A1 (pt)
AU (1) AU2003276594B2 (pt)
BR (1) BR0316310A (pt)
CA (1) CA2502025C (pt)
IL (1) IL168183A (pt)
MX (1) MXPA05005319A (pt)
NO (1) NO20051688L (pt)
NZ (1) NZ539923A (pt)
PL (1) PL377740A1 (pt)
RU (1) RU2401127C2 (pt)
TW (1) TWI267379B (pt)
WO (1) WO2004045646A1 (pt)
ZA (1) ZA200503040B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303026B1 (en) 2008-06-17 2020-09-09 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
EP2734246B1 (en) 2011-07-20 2019-02-27 Brigham Young University Hydrophobic ceragenin compounds and devices incorporating same
US9161942B2 (en) 2011-09-13 2015-10-20 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
EP2755661A1 (en) 2011-09-13 2014-07-23 Brigham Young University Compositions for treating bone diseases and broken bones
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
CN104379120A (zh) 2011-12-21 2015-02-25 布莱阿姆青年大学 口腔护理组合物
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
CA2872399C (en) 2012-05-02 2021-01-12 Brigham Young University Ceragenin particulate materials and methods for making same
AU2013331136B2 (en) 2012-10-17 2016-05-12 Brigham Young University Treatment and prevention of mastitis
CA2897150C (en) 2013-01-07 2021-07-13 Brigham Young University Methods for reducing cellular proliferation and treating certain diseases
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
AU2014234992B2 (en) 2013-03-15 2018-01-18 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
US9527883B2 (en) 2015-04-22 2016-12-27 Brigham Young University Methods for the synthesis of ceragenins
WO2016172543A1 (en) 2015-04-22 2016-10-27 Savage Paul B Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US110561A (en) * 1870-12-27 Improvement in children s carriages
US4297353A (en) 1980-08-04 1981-10-27 Sandoz, Inc. Non-irritating injectable dosage forms
ES8702440A1 (es) * 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
US5019395A (en) 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
JP2856444B2 (ja) * 1989-07-28 1999-02-10 呉羽化学工業株式会社 ビタミンｄ▲下３▼代謝産物製剤
JP3078859B2 (ja) 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
FR2692480B1 (fr) 1992-06-22 1995-12-08 Technico Flor Sa Nouvelles compositions cosmetiques ou alimentaires renfermant du copaiba.
PL184611B1 (pl) * 1993-03-12 2002-11-29 Upjohn Co Krystaliczny ceftiofur w postaci wolnego kwasu sposób jego wytwarzania oraz kompozycja farmaceutyczna zawierająca krystaliczny ceftiofur w postaci wolnego kwasu
DE4340879A1 (de) 1993-12-01 1995-06-08 Horst P O Dr Wolf Arzneimittel zur Behandlung der Herzinsuffizienz
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
EP0914126B1 (en) 1996-06-27 2003-08-27 Janssen Pharmaceutica N.V. Sustained release sufentanil compositions
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
WO2002022107A2 (en) * 2000-09-12 2002-03-21 Pharmacia & Upjohn Company Pharmaceutical composition having modified carrier
EP1317252A2 (en) * 2000-09-12 2003-06-11 PHARMACIA & UPJOHN COMPANY Pharmaceutical composition having specific water activity

Also Published As

Publication number Publication date
CN103272243A (zh) 2013-09-04
AU2003276594B2 (en) 2009-01-08
EP1569693A1 (en) 2005-09-07
IL168183A (en) 2010-04-29
US20040170650A1 (en) 2004-09-02
MXPA05005319A (es) 2005-07-25
TWI267379B (en) 2006-12-01
AR042193A1 (es) 2005-06-15
NO20051688L (no) 2005-08-02
TW200427466A (en) 2004-12-16
RU2005115131A (ru) 2005-10-27
CA2502025C (en) 2013-07-02
JP2006514629A (ja) 2006-05-11
CN1713923A (zh) 2005-12-28
AU2003276594A1 (en) 2004-06-15
CA2502025A1 (en) 2004-06-03
NO20051688D0 (no) 2005-04-05
WO2004045646A1 (en) 2004-06-03
PL377740A1 (pl) 2006-02-20
US7659061B2 (en) 2010-02-09
JP4656945B2 (ja) 2011-03-23
EP1569693B1 (en) 2016-12-28
ZA200503040B (en) 2006-09-27
NZ539923A (en) 2007-02-23
RU2401127C2 (ru) 2010-10-10
KR20050085037A (ko) 2005-08-29

Similar Documents

Publication Publication Date Title
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
CL2003002277A1 (es) Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente.
DK1162943T3 (da) Ikke-sviende coatingpræparat
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
BR0108238A (pt) Composições cosméticas contendo pelo menos um hetero polìmero e pelo menos uma resina de silicone de formação de pelìcula e métodos de empregá-las
BR0211390A (pt) Tratamento de infecções da unha com no
BR0015605A (pt) Composição e uso
BR0015197A (pt) Copolìmero vinìlico, e, composição
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
MXPA05001061A (es) Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol.
BR9811478A (pt) Composições de polìmero-ácido tânico para a liberação controlada de agentes farmacêuticos particularmente na cavidade oral
ECSP055566A (es) Formulaciones de depósito de corta duración
BR0109934A (pt) Preparação e prevenção de diarréia de ácido biliar
BR0003987A (pt) Composição laxativa
BR0007294A (pt) Formulações farmacêuticas aperfeiçoadas
BR0313428A (pt) Composições farmacêuticas de drogas semi-ordenados e polìmeros
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
ME00624B (me) Nova primjena docetaksela za liječenje hepatoma
BR0113148A (pt) Composições de 2-piridinamina e métodos relacionados
BRPI0611526A2 (pt) composição tópica contendo gelatina
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 47/44, A61K 47/14, A61K 31/545, A61P 31/00

Ipc: A61K 47/44 (2011.01), A61K 47/14 (2011.01), A61K 3

B15V Prolongation of time limit allowed

Free format text: RECONHECIDO OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 37 DIAS, NOS TERMOS DO ARTIGO 221 2O DA LPI E RESOLUCAO 116/04.

B25A Requested transfer of rights approved

Owner name: PAH PANDU LLC (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS PANDU LLC (US)

B25A Requested transfer of rights approved

Owner name: ZOETIS SERVICES LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]